Jump to content

Estradiol valerate/testosterone enanthate

Add links
From Wikipedia, the free encyclopedia
(Redirected from Ditate-DS)
Estradiol valerate /
testosterone enanthate
Estradiol valerate (top) and
testosterone enanthate (bottom)
Combination of
Estradiol valerateEstrogen
Testosterone enanthateAndrogen; Anabolic steroid
Clinical data
Trade namesDeladumone, Despamen, Ditate, Ditate-DS, Gravignost, Primodian Depot, Valertest, others
Other namesEV/TE; TEEV
Routes of
administration		Intramuscular injection
Identifiers
CAS Number
PubChem CID
UNII

Estradiol valerate/testosterone enanthate (EV/TE), sold under the brand names Primodian Depot and Ditate among others, is an injectable combination medication of estradiol valerate (EV), an estrogen, and testosterone enanthate (TE), an androgen/anabolic steroid, which is used in menopausal hormone therapy for women.[1][2] The medication is also used to suppress lactation in postpartum women (brand name Deladumone).[3][4][5][6]

Ditate was provided in the form of multi-use 10 mL vials containing 4 mg/mL EV and 90 mg/mL TE in an oil solution and was administered by intramuscular injection at regular intervals.[7] Conversely, another preparation, Ditate-DS, was provided in the form of single-use 2 mL vials containing 8 mg/mL EV and 180 mg/mL TE in an oil solution, and was administered as a single intramuscular injection.[7] Another product, Primodian Depot, was provided in the form of 1 mL ampoules containing 4 mg/mL EV (3.0 mg/mL free estradiol) and 90.3 mg/mL TE (65 mg/mL free testosterone) in an oil solution, and was administered by intramuscular injection once every 4 to 6 weeks.[8][9][10][11] The elimination half-life of EV in oil by intramuscular injection is approximately 4 or 5 days.[12] Similarly, the elimination half-life of TE in oil by intramuscular injection is approximately 4 or 5 days.[13] EV/TE reportedly has a duration of about 21 days.[14]

Deladumone OB was a double-dosage formulation of Deladumone, which was intended to provide the same dosage with a smaller injection volume.[15]

Primodian Depot was introduced for medical use by 1955.[16] An oral tablet product with the similar brand name of Primodian, containing ethinylestradiol and methyltestosterone, was marketed around the same time, and should not be confused with the injectable Primodian Depot.[8] EV/TE was discontinued in the United States by 2011.[17] EV/TE has been discontinued in most other countries as well, but formulations of EV/TE continue to be marketed in a few countries, including Japan, Mexico, Peru, and Taiwan.[18][19][20]

Androgen replacement therapy formulations and dosages used in women
Route Medication Major brand names Form Dosage
Oral Testosterone undecanoate Andriol, Jatenzo Capsule 40–80 mg 1x/1–2 days
Methyltestosterone Metandren, Estratest Tablet 0.5–10 mg/day
Fluoxymesterone Halotestin Tablet 1–2.5 mg 1x/1–2 days
Normethandronea Ginecoside Tablet 5 mg/day
Tibolone Livial Tablet 1.25–2.5 mg/day
Prasterone (DHEA)b – Tablet 10–100 mg/day
Sublingual Methyltestosterone Metandren Tablet 0.25 mg/day
Transdermal Testosterone Intrinsa Patch 150–300 μg/day
AndroGel Gel, cream 1–10 mg/day
Vaginal Prasterone (DHEA) Intrarosa Insert 6.5 mg/day
Injection Testosterone propionatea Testoviron Oil solution 25 mg 1x/1–2 weeks
Testosterone enanthate Delatestryl, Primodian Depot Oil solution 25–100 mg 1x/4–6 weeks
Testosterone cypionate Depo-Testosterone, Depo-Testadiol Oil solution 25–100 mg 1x/4–6 weeks
Testosterone isobutyratea Femandren M, Folivirin Aqueous suspension 25–50 mg 1x/4–6 weeks
Mixed testosterone esters Climacterona Oil solution 150 mg 1x/4–8 weeks
Omnadren, Sustanon Oil solution 50–100 mg 1x/4–6 weeks
Nandrolone decanoate Deca-Durabolin Oil solution 25–50 mg 1x/6–12 weeks
Prasterone enanthatea Gynodian Depot Oil solution 200 mg 1x/4–6 weeks
Implant Testosterone Testopel Pellet 50–100 mg 1x/3–6 months
Notes: Premenopausal women produce about 230 ± 70 μg testosterone per day (6.4 ± 2.0 mg testosterone per 4 weeks), with a range of 130 to 330 μg per day (3.6–9.2 mg per 4 weeks). Footnotes: a = Mostly discontinued or unavailable. b = Over-the-counter. Sources: See template.

See also

[edit]

References

[edit]
  1. ^ Shellenberger TE (6 December 2012). "Pharmacology of estrogens". In Notelovitz M, van Keep PA (eds.). The Climacteric in Perspective: Proceedings of the Fourth International Congress on the Menopause, held at Lake Buena Vista, Florida, October 28–November 2, 1984. Springer Science & Business Media. pp. 397–. doi:10.1007/978-94-009-4145-8_36. ISBN 978-94-009-4145-8.
  2. ^ Kahr H, Müller HA (1956). "Das Klimakterium". Konservative Therapie der Frauenkrankheiten. Springer. pp. 85–102. doi:10.1007/978-3-7091-5694-0_2. ISBN 978-3-7091-5696-4.
  3. ^ McNeilly AS (2011). "Physiology of lactation". Journal of Biosocial Science. 9 (S4): 5–21. doi:10.1017/S0021932000023804. ISSN 0021-9320. S2CID 24614184.
  4. ^ Vorherr H (July 1972). "Suppression of postpartum lactation". Postgraduate Medicine. 52 (1): 145–152. doi:10.1080/00325481.1972.11713186. PMID 5037562.
  5. ^ Vorherr H (2 December 2012). "Suppression of Lactation". The Breast: Morphology, Physiology, and Lactation. Elsevier Science. pp. 200–203. ISBN 978-0-323-15726-1.
  6. ^ Copeland Jr WE (1986). "Lactation Suppressants.". Drug Therapy in Obstetrics and Gynecology. p. 241.
  7. ^ a b de Haen P (1972). "Drugs Released for Clinical Use". The Journal of Clinical Pharmacology and New Drugs. 12 (1): 58–60. doi:10.1002/j.1552-4604.1972.tb00038.x. ISSN 0021-9754.
  8. ^ a b Hager HH, Kern W, List PH, Roth HJ (29 July 2013). "Gestagene, Progestagene". Hagers Handbuch der Pharmazeutischen Praxis: Für Apotheker, Arzneimittelhersteller, Ärzte und Medizinalbeamte: Wirkstoffgruppen II Chemikalien und Drogen (A-AL). Springer-Verlag. pp. 142, 156, 185. ISBN 978-3-662-25655-8.
  9. ^ Saure A (11 November 2013). "Hormonpräparate, die zur Behandlung der Wechseljahre eingesetzt werden". Die Wechseljahre der Frau: Hormone — Präparate — Therapien. Springer-Verlag. pp. 157–. ISBN 978-3-0348-6676-7.
  10. ^ Arends G, Zörnig H, Hager H, Frerichs G, Kern W (14 December 2013). "Hormone". Hagers Handbuch der pharmazeutischen Praxis: Für Apotheker, Arzneimittelhersteller, Drogisten, Ärzte u. Medizinalbeamte. Springer-Verlag. pp. 1164–. ISBN 978-3-662-36329-4.
  11. ^ Kaiser R (2 July 2013). "Ovar". In Buchborn E, Jahrmärker H, Karl HJ, Martini GA, Müller W, Riecker G, Schwiegk H, Siegenthaler W, Stich W (eds.). Therapie innerer Krankheiten. Springer-Verlag. pp. 405–. ISBN 978-3-662-10489-7.
  12. ^ Düsterberg B, Nishino Y (December 1982). "Pharmacokinetic and pharmacological features of oestradiol valerate". Maturitas. 4 (4): 315–324. doi:10.1016/0378-5122(82)90064-0. PMID 7169965.
  13. ^ Luetjens CM, Wistuba J, Weinbauer G, Nieschlag E (2007). "The Leydig Cell as a Target for Male Contraception". In Payne AH, Hardy MP (eds.). The Leydig Cell in Health and Disease. Contemporary Endocrinology. Humana Press. pp. 415–442. doi:10.1007/978-1-59745-453-7_29. ISBN 978-1-58829-754-9.
  14. ^ Ufer J (1 January 1978). Hormontherapie in der Frauenheilkunde: Grundlagen und Praxis [Hormone Therapy in Gynecology: Principles and Practice] (in German) (5th ed.). de Gruyter. p. 276. ISBN 978-3110066647. OCLC 924728827.
  15. ^ Physicians Desk Reference to Pharmaceutical Specialties and Biologicals. Medical Economics. 1971. p. 1262. Deladumone OB contains the same hormonal agents as Deladumone (Testosterone Enanthate and Estradiol Valerate Injection) but at twice the potency, in order to provide a high dosage concentration in a low volume.
  16. ^ Geburtshilfe und Frauenheilkunde: Ergebnisse der Forschung für die Praxis. Georg Thieme Verlag. 1955. pp. 1061–1062.
  17. ^ Food and Drug Administration (2011). Approved Drug Products with Therapeutic Equivalence Evaluations - FDA Orange Book 31st Edition (2011): FDA Orange Book 31st Edition (2011). DrugPatentWatch.com. pp. 586–. ISBN 978-1-934899-81-6.
  18. ^ "Estradiol". Drugs.com.
  19. ^ Sweetman SC, ed. (2009). "Sex hormones and their modulators". Martindale: The Complete Drug Reference (36th ed.). London: Pharmaceutical Press. pp. 2100, 2124–2125. ISBN 978-0-85369-840-1.
  20. ^ "IBM Watson Health Products: Please Login". www.micromedexsolutions.com.
Retrieved from "https://wiki.riteme.site/w/index.php?title=Estradiol_valerate/testosterone_enanthate&oldid=1241124489"